Call for nominations: Join the ERDERA Multistakeholder Advisory Board

ERDERA MAB

The European Rare Diseases Research Alliance (ERDERA) is excited to announce the call for nominations for its Multistakeholder Advisory Board (MAB). Our mission is to transform the landscape of rare disease research in Europe and improve the lives of over 30 million people living with rare diseases.

By supporting innovative research, developing new diagnostic methods, and spearheading digital transformation, ERDERA aims to create a collaborative and comprehensive ecosystem for rare disease (RD) research and patient care.

What does the MAB do?

The Multistakeholder Advisory Board (MAB) will provide strategic guidance to ERDERA, helping shape research and support activities that are directly aligned with patient needs. The MAB will play a key role in advising on clinical research, funding strategies, and collaboration opportunities.

We are looking for experts in:

  • Rare Disease Researchers & Geneticists
  • Healthcare Professionals
  • Public-Private Partnership & Industry Professionals
  • Digital Health & Data Scientists
  • Regulatory, HTA, & Policy Experts
  • Funding & Grant Management Specialists
  • Education & Training Professionals
  • Strategic Coordinators & Program Managers
  • Ethics & Patient Consent Experts
  • Legal Experts in Healthcare

MAB member expectations:

  • Initial term: 3 years, with the option to renew for 4 more years
  • Meet every four months, with at least one in-person meeting in the first year
  • Opportunity to form thematic groups to provide specialized advice

How to apply:

Interested in shaping the future of rare disease research? Submit your CV and Letter of Motivation to mab-erdera@ejprarediseases.org by October 31st, 2024, 6 PM CET.

We’re committed to selecting MAB members based on expertise, geographical diversity, gender balance, and conflict-of-interest considerations.

Join us in driving forward innovation in rare disease research!

Click here to find more information.

News & Updates

You might also be interested in

A legislative own initiative file in the Parliament’s new public health committee sets out what an EU “rare disease action framework” could look like — and why it could change how Europe measures progress for patients.
Drawing on Europe-wide patient and carer surveys, ERDERA highlights how gender can shape diagnostic delays, care burden and the evidence base for rare-disease research.
European Parliament research service assessment, published in February 2026, identifies 31 measures that could form an EU rare disease action plan, highlighting European Reference Networks and cross-border collaboration including ERDERA as drivers of EU added value.